Safety of mFOLFOX6/XELOX as adjuvant chemotherapy after curative resection of stage III colon cancer: Phase II clinical study (The FACOS study)
International Journal of Colorectal Disease Mar 06, 2018
Kosugi C, et al. - The purpose of the current study was to gauge the tolerability of modified FOLFOX6 (mFOLFOX6) and XELOX regimens in Japanese colon cancer patients. The findings did not reveak prominent variation in the frequency of grade ≥ 3 adverse events (AEs) between mFOLFOX6 and XELOX groups. Hence, it was determined that mFOLFOX6/XELOX regimens are acceptable as adjuvant chemotherapy for stage III colon cancer.
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty -
Paid Market Research Surveys -
Case discussions, News & Journals' summaries
